Literature DB >> 2006005

The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression.

T Caraceni1, G Scigliano, M Musicco.   

Abstract

The aim of this study is to evaluate what factors influence the risk of occurrence of motor fluctuations in patients with Parkinson's disease (PD) with particular reference to the role of early or delayed introduction of levodopa therapy during the course of the disease. One hundred twenty-five consecutive newly diagnosed patients with PD started levodopa treatment at the time diagnosis and were followed for 2 to 10 years. During follow-up, 60 patients had wearing-off or early morning akinesia. We estimated the cumulative time-dependent risk of motor fluctuation occurrence through a multivariable analysis. The risk was lower for patients with tremor-predominant PD, for those with shorter disease duration prior to levodopa, and for those who were relatively older at levodopa initiation. Our results suggest that, as far as motor fluctuations are concerned, disease prognosis is not influenced by early levodopa treatment. These observation support the introduction of levodopa as soon as there is a subjective need for the patients to maintain their level of social and work performance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2006005     DOI: 10.1212/wnl.41.3.380

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

Review 1.  Early detection of Parkinson's disease. Implications for treatment.

Authors:  R Di Paola; R J Uitti
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

2.  A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

Authors:  J L Montastruc; O Rascol; J M Senard; A Rascol
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

Review 3.  Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?

Authors:  M G Murer; R Raisman-Vozari; O Gershanik
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 4.  Does levodopa accelerate Parkinson's disease?

Authors:  T Simuni; M B Stern
Journal:  Drugs Aging       Date:  1999-06       Impact factor: 3.923

5.  Parkinson's Disease: Initial Treatment with Levodopa or Dopamine Agonists.

Authors:  Stewart A. Factor
Journal:  Curr Treat Options Neurol       Date:  2001-11       Impact factor: 3.598

6.  The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa.

Authors:  M A Hely; J G Morris; W G Reid; D J O'Sullivan; P M Williamson; D Rail; G A Broe; S Margrie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

7.  A multicenter Italian randomised study on early treatment of Parkinson disease: comparison of L-dopa, l-deprenyl and dopaminoagonists. Study design and short term results. The Italian Parkinson Study Group.

Authors: 
Journal:  Ital J Neurol Sci       Date:  1992-12

8.  Age-related decrease in responsiveness to L-DOPA is not due to changes in dopamine receptor mRNAs or G protein mRNAs.

Authors:  M Murata; Y Aihara; H Yamanouchi; S Yamada; I Kanazawa
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

9.  Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs.

Authors:  Yoshikuni Mizuno; Satoe Shimoda; Hideki Origasa
Journal:  J Neural Transm (Vienna)       Date:  2017-01-16       Impact factor: 3.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.